# Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants

> **NCT00290303** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 996 (actual)

## Conditions studied

- Haemophilus Influenzae Type b
- Diphtheria
- Whole Cell Pertussis
- Hepatitis B
- Tetanus

## Interventions

- **BIOLOGICAL:** DTPw-HBV/Hib-MenAC conjugate vaccine

## Key facts

- **NCT ID:** NCT00290303
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2005-03
- **Final completion:** 2005-03
- **Target enrollment:** 996 (ACTUAL)
- **Last updated:** 2016-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00290303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00290303, "Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00290303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*